Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV
Maurice Michel, Christian Labenz, Malena Anders, Alisha Wahl, Lisann Girolstein, Leonard Kaps, Wolfgang M. Kremer, Yvonne Huber, Peter R. Galle, Martin Sprinzl, Jörn M. Schattenberg – 11 April 2022 – Hepatic steatosis (HS) related to nonalcoholic fatty liver disease (NAFLD) is increasing globally. In people living with human immunodeficiency virus (PLWH) risk factors of HS are increased. The impact of HS on outcomes and in particular health‐related quality of life (HRQL) in PLWH remains unknown.